Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACAD NASDAQ:APLS NASDAQ:BCAX NASDAQ:MIRM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.02+1.3%$23.24$13.40▼$26.65$3.72B0.752.10 million shs1.38 million shsAPLSApellis Pharmaceuticals$28.17-1.5%$25.60$16.10▼$35.72$3.56B0.692.46 million shs1.27 million shsBCAXBicara Therapeutics$17.14+1.3%$13.85$7.80▼$28.09$936.05MN/A875,773 shs660,674 shsMIRMMirum Pharmaceuticals$70.02+0.9%$73.03$36.88▼$78.54$3.52B0.81625,389 shs320,724 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+5.41%+3.82%-5.29%+54.09%APLSApellis Pharmaceuticals0.00%+14.89%+26.78%+43.80%+4.41%BCAXBicara Therapeutics0.00%-6.08%+60.19%+45.87%-23.75%MIRMMirum Pharmaceuticals0.00%-4.77%-4.83%+35.10%+82.25%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACADACADIA Pharmaceuticals$22.02+1.3%$23.24$13.40▼$26.65$3.72B0.752.10 million shs1.38 million shsAPLSApellis Pharmaceuticals$28.17-1.5%$25.60$16.10▼$35.72$3.56B0.692.46 million shs1.27 million shsBCAXBicara Therapeutics$17.14+1.3%$13.85$7.80▼$28.09$936.05MN/A875,773 shs660,674 shsMIRMMirum Pharmaceuticals$70.02+0.9%$73.03$36.88▼$78.54$3.52B0.81625,389 shs320,724 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACADACADIA Pharmaceuticals0.00%+5.41%+3.82%-5.29%+54.09%APLSApellis Pharmaceuticals0.00%+14.89%+26.78%+43.80%+4.41%BCAXBicara Therapeutics0.00%-6.08%+60.19%+45.87%-23.75%MIRMMirum Pharmaceuticals0.00%-4.77%-4.83%+35.10%+82.25%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACADACADIA Pharmaceuticals 2.65Moderate Buy$29.3333.21% UpsideAPLSApellis Pharmaceuticals 2.47Hold$33.4718.82% UpsideBCAXBicara Therapeutics 2.75Moderate Buy$31.8685.87% UpsideMIRMMirum Pharmaceuticals 3.00Buy$79.7013.82% UpsideCurrent Analyst Ratings BreakdownLatest BCAX, ACAD, APLS, and MIRM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/25/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/24/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/21/2025APLSApellis PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy10/21/2025ACADACADIA PharmaceuticalsCitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform ➝ Buy$33.0010/16/2025MIRMMirum PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$75.00 ➝ $81.0010/15/2025APLSApellis PharmaceuticalsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Overweight$29.00 ➝ $32.0010/14/2025ACADACADIA PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/14/2025BCAXBicara TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025APLSApellis PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025MIRMMirum PharmaceuticalsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/29/2025ACADACADIA PharmaceuticalsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$34.00 ➝ $33.00(Data available from 10/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACADACADIA Pharmaceuticals$957.80M3.88$0.70 per share31.24$4.40 per share5.00APLSApellis Pharmaceuticals$781.37M4.55N/AN/A$1.84 per share15.31BCAXBicara TherapeuticsN/AN/AN/AN/A$9.04 per shareN/AMIRMMirum Pharmaceuticals$336.89M10.44N/AN/A$4.70 per share14.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACADACADIA Pharmaceuticals$226.45M$1.3316.5628.977.6121.80%14.69%9.41%11/5/2025 (Estimated)APLSApellis Pharmaceuticals-$197.88M-$1.82N/AN/AN/A-30.24%-116.09%-26.72%10/30/2025 (Estimated)BCAXBicara Therapeutics-$68M-$3.17N/AN/AN/AN/A-21.67%-20.89%11/11/2025 (Estimated)MIRMMirum Pharmaceuticals-$87.94M-$1.21N/AN/AN/A-13.65%-24.76%-8.50%11/11/2025 (Estimated)Latest BCAX, ACAD, APLS, and MIRM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/11/2025Q3 2025BCAXBicara Therapeutics-$0.55N/AN/AN/AN/AN/A11/11/2025Q3 2025MIRMMirum Pharmaceuticals-$0.11N/AN/AN/A$130.11 millionN/A11/5/2025Q3 2025ACADACADIA Pharmaceuticals$0.14N/AN/AN/A$276.52 millionN/A10/30/2025Q3 2025APLSApellis Pharmaceuticals$0.73N/AN/AN/A$364.58 millionN/A8/12/2025Q2 2025BCAXBicara Therapeutics-$0.54-$0.50+$0.04-$0.50N/AN/A8/6/2025Q2 2025ACADACADIA Pharmaceuticals$0.14$0.16+$0.02$0.16$263.07 million$264.57 million8/6/2025Q2 2025MIRMMirum Pharmaceuticals-$0.31-$0.12+$0.19-$0.12$107.91 million$127.79 million7/31/2025Q2 2025APLSApellis Pharmaceuticals-$0.44-$0.33+$0.11-$0.33$187.91 million$171.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACADACADIA PharmaceuticalsN/AN/AN/AN/AN/AAPLSApellis PharmaceuticalsN/AN/AN/AN/AN/ABCAXBicara TherapeuticsN/AN/AN/AN/AN/AMIRMMirum PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACADACADIA PharmaceuticalsN/A2.912.83APLSApellis Pharmaceuticals2.903.773.16BCAXBicara TherapeuticsN/A25.8025.80MIRMMirum Pharmaceuticals1.213.132.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACADACADIA Pharmaceuticals96.71%APLSApellis Pharmaceuticals96.29%BCAXBicara TherapeuticsN/AMIRMMirum PharmaceuticalsN/AInsider OwnershipCompanyInsider OwnershipACADACADIA Pharmaceuticals26.50%APLSApellis Pharmaceuticals6.50%BCAXBicara Therapeutics15.50%MIRMMirum Pharmaceuticals14.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACADACADIA Pharmaceuticals510168.71 million124.00 millionOptionableAPLSApellis Pharmaceuticals770126.29 million118.08 millionOptionableBCAXBicara Therapeutics3254.61 million46.15 millionN/AMIRMMirum Pharmaceuticals14050.24 million43.02 millionOptionableBCAX, ACAD, APLS, and MIRM HeadlinesRecent News About These CompaniesCantor Fitzgerald Remains a Buy on Mirum Pharmaceuticals (MIRM)October 25 at 11:52 AM | theglobeandmail.comQ3 EPS Forecast for Mirum Pharmaceuticals Raised by AnalystOctober 19, 2025 | americanbankingnews.comEquities Analysts Set Expectations for MIRM FY2026 EarningsOctober 18, 2025 | americanbankingnews.comLeerink Partnrs Has Optimistic Outlook of MIRM Q3 EarningsOctober 17, 2025 | marketbeat.comMorgan Stanley Maintains Mirum Pharmaceuticals (MIRM) Overweight RecommendationOctober 17, 2025 | msn.comMirum Pharmaceuticals price target raised to $81 from $75 at Morgan StanleyOctober 16, 2025 | msn.comWhat is Leerink Partnrs' Estimate for MIRM FY2026 Earnings?October 16, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives $76.50 Consensus Price Target from BrokeragesOctober 16, 2025 | americanbankingnews.comWill Livmarli Continue to Drive Mirum's Top Line in Q3 Earnings?October 14, 2025 | zacks.comOak Ridge Investments LLC Invests $922,000 in Mirum Pharmaceuticals, Inc. $MIRMOctober 13, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Reaches New 1-Year High - Time to Buy?October 11, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Given Consensus Recommendation of "Buy" by AnalystsOctober 11, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Receives Average Rating of "Buy" from AnalystsOctober 11, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Shares Up 6.9% - Should You Buy?October 10, 2025 | marketbeat.comMirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 10, 2025 | businesswire.comMirum Pharmaceuticals' (MIRM) "Sell (D-)" Rating Reiterated at Weiss RatingsOctober 10, 2025 | marketbeat.comMirum Pharmaceuticals, Inc. $MIRM Shares Sold by Wealth Enhancement Advisory Services LLCOctober 5, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Upgraded at Wall Street ZenSeptember 26, 2025 | marketbeat.comMirum Pharmaceuticals (NASDAQ:MIRM) Raised to Strong-Buy at TD CowenSeptember 26, 2025 | marketbeat.comMirum draws new Buy at TD Cowen on growth prospectsSeptember 26, 2025 | msn.comTD Cowen Initiates Coverage of Mirum Pharmaceuticals (MIRM) with Buy RecommendationSeptember 25, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCAX, ACAD, APLS, and MIRM Company DescriptionsACADIA Pharmaceuticals NASDAQ:ACAD$22.02 +0.29 (+1.33%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$21.99 -0.03 (-0.14%) As of 10/24/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.Apellis Pharmaceuticals NASDAQ:APLS$28.17 -0.44 (-1.54%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$27.24 -0.93 (-3.30%) As of 10/24/2025 07:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops APL-3007, a small interfering RNA, or siRNA, which is in a Phase 1 clinical trial, as well as an oral complement inhibitor that is in preclinical development. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.Bicara Therapeutics NASDAQ:BCAX$17.14 +0.22 (+1.30%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$17.70 +0.56 (+3.24%) As of 10/24/2025 07:54 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.Mirum Pharmaceuticals NASDAQ:MIRM$70.02 +0.61 (+0.88%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$70.04 +0.02 (+0.03%) As of 10/24/2025 04:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 10/20 - 10/24 Freeport-McMoRan Posts Strong Earnings Despite Indonesia Shutdown Tractor Supply Stock Looks Like a Buy-and-Hold Winner Tesla’s Earnings Review: Does the Juice Justify the Squeeze? Warner Bros. Bidding War Potential: How High Could WBD Shares Go? Fal.Con Europe Could Be CrowdStrike’s Early Earnings Catalyst Logitech Eyes Breakout Before Earnings—Citigroup Sees 30% Upside Boeing Takes Off as FAA Greenlights 737 MAX Production Boost Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
